Company intelligence / Profile preview

IMMCURE

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

ImmCure is a clinical-stage biotechnology company headquartered in Shenzhen, China, specializing in the development of innovative cell therapies for oncology. The company utilizes its proprietary platforms to design and manufacture CAR-T, CAR-NK, and TCR-T cell products aimed at treating both hematological cancers and solid tumors. Its lead program, IMC-001, is a BCMA-targeted CAR-T therapy currently being evaluated for the treatment of relapsed or refractory multiple myeloma. ImmCure is committed to advancing the field of immunotherapy through rigorous research and strategic collaborations to address unmet medical needs.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapyNK cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on IMMCURE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMMCURE.

Explore the full profile